Akeso and Summit Therapeutics said updated Phase 3 data for ivonescimab cleared the overall survival bar in a specific lung cancer setting, building on earlier interim results that had raised investor questions. The PD-1xVEGF bispecific reportedly showed longer survival versus the control arm in the trial cohort described by the companies, with full data not yet detailed in the release. Regulators are expected to scrutinize the strength and transferability of outcomes, while a global dataset is still anticipated for future regulatory discussions. The update keeps competitive pressure on the emerging class of dual-acting immune bispecifics.